Premium
Serum Fatty Acid‐Binding Protein 4 is Increased in Patients with Psoriasis
Author(s) -
Baran A.,
Świderska M.,
BacharewiczSzczerbicka Joanna,
Myśliwiec H.,
Flisiak I.
Publication year - 2017
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/s11745-016-4211-4
Subject(s) - psoriasis , medicine , metabolic syndrome , fatty acid binding protein , body mass index , psoriasis area and severity index , inflammation , gastroenterology , endocrinology , immunology , obesity , biology , biochemistry , gene
Psoriasis is associated with metabolic syndrome and cardiovascular disease. Fatty acid‐binding proteins (FABP) have been recognized as predictors of these systemic disorders. The aim of this study was to assess correlations between levels of serum heart and adipocyte fatty acid‐binding proteins (FABP3, FABP4) and disease severity, indicators of inflammation or metabolic disturbances, and topical treatment in psoriatic patients. Thirty‐seven patients with relapse of plaque‐type psoriasis and 16 healthy volunteers were recruited. Blood samples were collected before and after 14 days of therapy. Serum FABP concentrations were examined by enzyme‐linked immunosorbent assay for correlation with Psoriasis Area and Severity Index (PASI), body mass index (BMI), inflammatory or metabolic parameters, and treatment used. The median FABP4 serum levels were significantly increased ( p = 0.038) in psoriatic patients, while FABP3 levels did not differ ( p = 0.47) compared to the controls. No significant correlations were noted between the proteins and PASI, C‐reactive protein (CRP), BMI, or levels of glucose or lipids. FABP3 significantly correlated with white blood count ( p = 0.03) and aspartate aminotransferase ( p = 0.04). After topical treatment, there was no significant change in serum FABP3 [11.5 (4.9–30.3) vs. 12.9 (3.5–30.3) ng/ml] ( p = 0.96), whereas FABP4 was decreased [27,286 (20,344–32,257) vs. 23,034 (18,320–29,874) pg/ml] ( p = 0.12), losing its basal significance. FABP4 may be a marker of psoriasis, and FABP3 may be associated with inflammation or liver disorders in psoriatic patients. FABP do not appear to be useful for determining disease severity or the effectiveness of antipsoriatic treatment.